Table 2.

Adverse events (AE) of treated patients

n=79 patients	Grade 1–2		Grade 3		Grade 4
	No	%	No	%	No	%
Non immune-relate AE appearing in ≥5% of patients (non-irAE)
Alopecia	64	(81)	0		0
Fatigue	52	(66)	8	(10)	0
Xerostomia	55	(70)	4	(5)	0
Dysphagia	15	(19)	42	(53)	0
Infection	29	(37)	23	(29)	2	(3)
Leukopenia	13	(16)	31	(39)	10	(13)
Stomatitis	40	(51)	11	(14)	0
Radiation dermatitis	42	(53)	7	(9)	0
Nausea	41	(52)	3	(4)	0
Pain	38	(48)	5	(6)	0
Pruritus	37	(47)	0		0
Constipation	32	(41)	0		0
Vertigo	30	(38)	1	(1)	0
Lymph edema	30	(38)	0		0
Vomiting	25	(32)	1	(1)	0
Oral thrush	25	(32)	0		0
Polyneuropathy	23	(29)	0		0
Thrombocytopenia	20	(25)	0		0
Hypokalemia	13	(16)	3	(4)	0
Dyspnea	15	(19)	0		0
PEG/catheter complication	10	(13)	5	(6)	0
Hoarseness	14	(18)	0		0
Renal insufficiency	10	(13)	3	(4)	1	(1)
Subcutaneous fibrosis	13	(16)	0		0
Hyperpigmentation	12	(15)	0		0
Anemia	8	(10)	3	(4)	0
Hearing disorder	11	(14)	0		0
Ear disorder	9	(11)	1	(1)	0
Hyponatremia	4	(5)	4	(5)	0
Bleeding	5	(6)	1	(1)	1	(1)
Edema	6	(8)	1	(1)	0
Dysgenusia	4	(5)	1	(1)	0
Weight loss	3	(4)	2	(3)	0
Ulcus (tumor location)	3	(4)	0		1	(1)
Trism	4	(5)	0		0
Any possibly irAE
Diarrhea/colitis	40	(51)	5	(6)	0
Skin reaction	27	(34)	0		0
Elevated transaminases/ hepatitis	7	(9)	6	(8)	2	(3)
Hypothyroidism	14	(18)	1	(1)	0
Hyperthyroidism	14	(18)	0		0
Arthritis	4	(5)	1	(1)	0
Increased lipase/pancreatitis	0		3	(4)	0
Adrenalitis	0		2	(3)	0
Hypophysitis	0		2	(3)	0
Nephritis	1	(1)	1	(1)	0
Pneumonitis	0		0		1	(1)

Non-irAE appearing in at least 5% of patients independent from relationship to treatment and all possibly irAE.

PEG, percutaneous endoscopic gastrostomy.